D-dimer level and the risk for thrombosis in systemic lupus erythematosus

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 6, 2008, Pages 1628-1636

  Wu, Haifeng ^a   Birmingham, Daniel J ^a   Rovin, Brad ^a   Hackshaw, Kevin V ^a   Haddad, Nabil ^a   Haden, Douglas ^a   Yu, Chack Yung ^a   Hebert, Lee A ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; FEMALE; HUMAN; IMMUNOLOGY; LONGITUDINAL STUDY; MALE; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; TIME; UPREGULATION;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; BIOLOGICAL MARKERS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TIME FACTORS; UP-REGULATION; YOUNG ADULT;

EID: 58149336988     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01480308     Document Type: Article

References (49)

1. Asherson RA, Pierangeli SS, Cervera R: Is there a microangiopathic antiphospholipid syndrome? Ann Rheum Dis 66: 429-432, 2007
2. Petri MA: Clinical and management aspects of the antiphospholipid antibody syndrome. In: Dubois' Lupus Erythematosus, edited by Wallace DJ, Hahn BH, Philadelphia, Lippincott Willhams & Wilkins, 2007, pp 1262-1297
3. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, Triplett DA, Khamashta MA: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 42: 1309-1311, 1999
4. Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, Davis A, Sammaritano L, Levine DM, Salmon JE: Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 54: 3918-3925, 2006
5. Zavaleta NE, Montes RM, Soto ME, Vanzzini NA, Amigo MC: Primary antiphospholipid syndrome: A 5-year transesophageal echocardiographic followup study. J Rheumatol 31: 2402-2407, 2004
6. Handke M, Harloff A, Olschewski M, Hetzel A, Geibel A: Patent foramen ovale and cryptogenic stroke in older patients. N Engl J Med 357: 2262-2268, 2007
7. Ben-Ami D, Bar-Meir E, Shoenfeld Y: Stenosis in antiphospholipid syndrome: A new finding with clinical implications. Lupus 15: 466-472, 2006
8. Asherson RA, Pierangeli S, Cervera R: Microangiopathic antiphospholipid-associated syndromes revisited new concepts relating to antiphospholipid antibodies and syndromes. J Rheumatol 34: 1793-1795, 2007
9. Johnson SR, Gladman DD, Urowitz MB, Ibanez D, Granton JT: Pulmonary hypertension in systemic lupus. Lupus 13: 506-509, 2004
10. Asherson RA, Cervera R: Review: Antiphospholipid antibodies and the lung. J Rheumatol 22: 62-66, 1995
11. Li EK, Tam LS: Pulmonary hypertension in systemic lupus erythematosus: Clinical association and survival in 18 patients. J Rheumatol 26: 1923-1929, 1999
12. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groct PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M: Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46: 1019-1027, 2002
13. De Clerck LS, Michielsen PP, Ramael MR, Janssens E, Van Maercke YM, Van Marck EA, Stevens WJ: Portal and pulmonary vessel thrombosis associated with systemic lupus erythematosus and anticardiolipin antibodies. J Rheumatol 18: 1919-1921, 1991
14. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, Lim E, Lau TC, Gurjal A, Jedryka-Goral A, Chwalinska-Sadowska H, Dibner RJ, Rojas-Rodriguez J, Garcia-Carrasco M, Grandone JT, Parke AL, Barbosa P, Vasconcelos C, Ramos-Casals M, Font J, Ingelmo M: Catastrophic antiphospholipid syndrome: Clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80: 355-377, 2001
15. Paran D, Fireman E, Elkayam O: Pulmonary disease in systemic lupus erythematosus and the antiphospholipid syndrome. Autoimmun Rev 3: 70-75, 2004
16. Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GR: Pulmonary hypertension in a lupus clinic: Experience with twenty-four patients. J Rheumatol 17: 1292-1298, 1990
17. Abramson SB, Dobro J, Eberle MA, Benton M, Reibman J, Epstein H, Rapoport DM, Belmont HM, Goldring RM: Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med 114: 941-947, 1991
18. Shitrit D, Bendayan D, Bar-Gil-Shitrit A, Huerta M, Rudensky B, Fink G, Kramer MR: Significance of a plasma D-dimer test in patients with primary pulmonary hypertension. Chest 122: 1674-1678, 2002
19. Daugas E, Nochy D, Huong DL, Duhaut P, Beaufils H, Caudwell V, Bariety J, Piette JC, Hill G: Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 13: 42-52, 2002
20. Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC, Ruggeri M, Pogliani EM, Gamba G, Rossi E, Baudo F, Manotti C, D'Angelo A, Palareti G, De Stefano V, Berrettini M, Barbui T: Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 100: 530-536, 1996
21. Lockshin MD, Druzin ML, Goei S, Qamar T, Magid MS, Jovanovic L, Ferenc M: Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 313: 152-156, 1985
22. Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler HJ, Alam Z, Carey JL: IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death: A prospective cohort study. Stroke 28: 1660-1665, 1997
23. Bertolaccini ML, Khamashta MA: Laboratory diagnosis and management challenges in the antiphospholipid syndrome. Lupus 15: 172-178, 2006
24. Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GR: Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: Analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 162: 1164-1169, 2002
25. Shapiro SS, Spurgeon SE: Hematology: Coagulation problems. In: Systemic Lupus Erythematosus, 4th Ed., edited by Lahita RG, New York, Elsevier Academic Press, 2004, pp 1139-1160
26. Lockshin MD, Erkan D: Treatment of the antiphospholipid syndrome. N Engl J Med 349: 1177-1179, 2003
27. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349: 1133-1138, 2003
28. Tripodi A, Mannucci PM: Markers of activated coagulation and their usefulness in the clinical laboratory. Clin Chem 42: 664-669, 1996
29. Shrivastava S, Ridker PM, Glynn RJ, Goldhaber SZ, Moll S, Bounameaux H, Bauer KA, Kessler CM, Cushman M: D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost 4: 1208-1214, 2006
30. Kevorkian JP, Halimi C, Segrestaa JM, Drouet L, Soria C: Monitoring of patients with deep-vein thrombosis during and after anticoagulation with D-dimer. Lancet 351: 571-572, 1998
31. Mannarino E, Schillaci G: D-dimer and duration of anticoagulation. N Engl J Med 356: 421, author reply 423, 2007
32. Eichinger S, Minar E, Bialonczyk C, Hirschl M, Quehenberger P, Schneider B, Weltermann A, Wagner O, Kyrle PA: D-dimer levels and risk of recurrent venous thromboembolism. JAMA 290: 1071-1074, 2003
33. Marder VJ, Zareba W, Horan JT, Moss AJ, Kanouse JJ: Automated latex agglutination and ELISA testing yield equivalent D-dimer results in patients with recent myocardial infarction. THROMBO Research Investigators. Thromb Haemost 82: 1412-1416, 1999
34. Vidula H, Tian L, Liu K, Criqui MH, Ferrucci L, Pearce WH, Greenland P, Green D, Tan J, Garside DB, Guralnik J, Ridker PM, Rifai N, McDermott MM: Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: A cohort study. Ann Intern Med 148: 85-93, 2008
35. Qaseem A, Snow V, Barry P, Hornbake ER, Rodnick JE, Tobolic T, Ireland B, Segal JB, Bass EB, Weiss KB, Green L, Owens DK: Current diagnosis of venous thromboembolism in primary care: A clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 146: 454-458, 2007
36. Hofstee HM: Appropriateness of excluding pulmonary embolism. Ann Intern Med 145: 152, author reply 152, 2006
37. Di Nisio M, Squizzato A, Rutjes AW, Buller HR, Zwinderman AH, Bossuyt PM: Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: A systematic review. J Thromb Haemost 5: 296-304, 2007
38. Rovin BH, Tang Y, Sun J, Nagaraja HN, Hackshaw KV, Gray L, Rice R, Birmingham DJ, Yu CY, Spetie DN, Aziz A, Hebert LA: Clinical significance of fever in the SLE patient receiving steroid therapy. Kidney Int 68: 747-759, 2005
39. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN: Urine chemokines as biomarkers of human SLE activity. J Am Soc Nephrol 16: 467-473, 2005
40. Rovin BH, Song H, Hebert LA, Nadasdy T, Nadasdy G, Birmingham DJ, Yung Yu C, Nagaraja HN: Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int 68: 1825-1833, 2005
41. Birmingham DJ, Gavit KF, McCarty SM, Yu CY, Rovin BH, Nagaraja HN, Hebert LA: Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare. Clin Exp Immunol 143: 274-280, 2006
42. Birmingham DJ, Nagaraja HN, Rovin BH, Spetie L, Zhao Y, Li X, Hackshaw KV, Yu CY, Malarkey WB, Hebert LA: Fluctuation in self-perceived stress and increased risk of flare in patients with lupus nephritis carrying the serotonin receptor 1A-1019 G allele. Arthritis Rheum 54: 3291-3299, 2006
43. Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, Zhou B, Hebert M, Jones KN, Shu Y, Kitzmiller K, Blanchong CA, McBride KL, Higgins GC, Rennebohm RM, Rice RR, Hackshaw KV, Roubey RA, Grossman JM, Tsao BP, Birmingham DJ, Rovin BH, Hebert LA, Yu CY: Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): Low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 80: 1037-1054, 2007
44. Rovin BH, Birmingham DJ, Nagaraja HN, Yu CY, Hebert LA: Biomarker discovery in human SLE nephritis. Bull NYU Hosp Jt Dis 65: 187-193, 2007
45. Birmingham DJ, Rovin BH, Shidham G, Nagaraja HN, Zou X, Bissell M, Yu CY, Hebert LA: Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. Kidney Int 72: 865-870, 2007
46. Brandt JT, Barna LK, Triplett DA: Laboratory identification of lupus anticoagulants: Results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 74: 1597-1603, 1995
47. Roubey RA: New approaches to prevention of thrombosis in the antiphospholipid syndrome: Hopes, trials, and tribulations. Arthritis Rheum 48: 3004-3008, 2003
48. Ruiz-Irastorza G, Egurbide MV, Martinez-Berriotxoa A, Ugalde J, Aguirre C: Antiphospholipid antibodies predict early damage in patients with systemic lupus erythematosus. Lupus 13: 900-905, 2004
49. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, Unalp-Arida A, Vilela V, Yazici Y, Lockshin MD: Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56: 2382-2391, 2007